Literature DB >> 205361

Intratumor chemoimmunotherapy with mitomycin C and components from mycobacteria in regression of line 10 tumors in guinea pigs.

C A McLaughlin, J L Cantrell, E Ribi, E P Goldberg.   

Abstract

Intratumor chemotherapy with the use of mitomycin C and/or immunotherapy caused regression of line 10 carcinomas in strain 2 guinea pigs and resulted in development of tumor-specific immunity. The immunotherapeutic preparation consisted of oil-in-water emulsions containing Mycobacterium cell walls or residues of cell walls termed cell wall skeletons. The latter preparations were combined with trehalose dimycolate, which was isolated by microparticulate chromatography from whole cells of mycobacteria. Reducing mitomycin C to a single intratumor injection of 50 microgram produced little necrotizing effect and a mean tumor regression rate of 17%. Intratumor immunotherapy 1 day after treatment with 50 microgram of mitomycin C resulted in regression of 90% of the treated tumors as compared to mean regression rates of 30 to 50% for immunotherapy alone. In addition, chemoimmunotherapy was more effective than either chemotherapy or immunotherapy alone in producing regression of relatively large, as well as smaller, tumors.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 205361

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Pharmacokinetic analysis of drug disposition after intratumoral injection in a tissue-isolated tumor perfusion system.

Authors:  A Saikawa; T Nomura; F Yamashita; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

2.  Intratumoural administration of cisplatin in slow-release devices. I. Tumour response and toxicity.

Authors:  M J Deurloo; S Bohlken; W Kop; C F Lerk; W Hennink; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Analysis of therapeutic effect in experimental chemoimmunotherapy for rat ascites tumor.

Authors:  T Ogura; O Shinzato; M Sakatani; H Shindo; M Namba; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.